Tariquidar: QLTI started 2 double-blind North American and European Phase III trials of tariquidar as an adjunctive treatment in combination with first-line che

QLT Inc. (QLTI; TSE:QLT), Vancouver, B.C.
Product: Tariquidar (XR9576)
Business: Cancer
Therapeutic category: Adjunct
Target:

Read the full 159 word article

How to gain access

Continue reading with a
two-week free trial.